4th IMPAKT Breast Cancer Conference

IMPAKT - Improving care and knowledge through translational research

A unique Breast Cancer Conference that bridges the gap between research and clinic while also providing the right environment for young professionals to network with and access the knowledge of their senior counterparts.

IMPAKT is an annual conference that was launched in 2009 by the Breast International Group (BIG) and the European Society for Medical Oncology (ESMO), in collaboration with a multidisciplinary alliance of European breast cancer organisations and patient groups - referred to as partners. Partners include the Foundation St. Gallen Oncology Conferences, the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group, the European Society of Breast Cancer Specialists (EUSOMA), and Europa Donna – the European Breast Cancer Coalition.

IMPAKT focuses on translational research in breast cancer and on innovative ways of developing new agents. It is a valuable meeting which brings together pre-clinical and clinical researchers from Academia and Industry, junior and senior oncologists and facilitates the role of mentor and the importance of sharing knowledge to improve careers. The rapid translation of biologically-based laboratory discoveries into daily clinical practice is important, but equally important is the trip back from the clinic to the laboratory, to further explore and explain clinically observed tumor biology and behavior.
+ show speakers and program
1 | P a g e
4
th
IMPAKT Breast Cancer Conference
3-5 May 2012, Brussels, Belgium
Pre-IMPAKT Training Course
PROGRAM
Wednesday, 2 May 2012
12:15-12:45 Welcome and Lunch
12:45-13:00 Introduction
Career planning in translational research Fabrice André, FR and Sherene Loi, BE
13:00-14:00 PI3K- from mice to breast cancer patients Chair: Sherene Loi, BE
Biology of PI3K Lewis Cantley, US
PIK3CA, PTEN and AKT gene alteration in
human breast cancer: Biomarkers for increased
PI3K pathway activity
Bryan Hennessy, IE
14:00-15:30
Concepts in drug development: Illustration
based on PI3K inhibitors
Chair: Fabrice André, FR
Early phase drug development, a clinician’s
perspective
Javier Cortes, ES
Early phase drug development, a pharma
viewpoint
Malte Peters, CH
Incorporating biomarkers into early phase
clinical trials, a statistical viewpoint
Stefan Michiels, BE
Discussion
15:30-16:00 Coffee break
16:00-18:00
Translational research on Host-tumor
interactions: Hot topics, experimental
techniques, how, what and why with
emphasis on translation
Moderator: Bryan Hennessy, IE
Monitoring angiogenesis Jean-Yves Pierga, FR
Tumor-stroma interactions Charlotte Kuperwasser, US
Interrogating the immune system Mark J. Smyth, AU
Discussion
18:00-18:30 Cocktail
Thursday, 3 May 2012
08:30-10:00 New technologies update (1) Moderator: Sherene Loi, BE
Next generation sequencing: How can it
improve my research projects?
Jorge Reis-Filho, GB
Gene expression: What’s new Christine Desmedt, BE
MiRNA: What’s new, hot topics, technologies -
advantages and disadvantages
Stephan Vagner, FR
10:00-10:30 Coffee break
10:30-12:00 New technologies update (2) Moderator: Fabrice André, FR
SiRNA screens: How can it help research Charles Swanton, GB
Quantifying kinase activity in human samples Thierry Dubois, FR
Circulating tumor cells Michail Ignatiadis, BE
12:00-13:00 Lunch 2 | P a g e
IMPAKT Breast Cancer Conference
PROGRAM
Thursday, 3 May 2012
11:00-12:00 Satellite symposium/Special session TBC
11:00-12:00 Press Conference
12:15-12:30 Official welcome
Martine Piccart, BE and José Baselga, US
Fabrice André, FR and Sherene Loi, BE
12:30-13:15 Opening keynote lecture
Co-Chairs: Larry Norton, US and José
Baselga, US
Targeting PI3K/AKT/mTOR pathway in breast
cancer
Lewis Cantley, US
Clinical perspectives and implications for
biomarker development
José Baselga, US
13:15-14:00
Recent advances in translational research –
an update
Co-Chairs: Michael Gnant, AT and HansJörg Senn, CH
Update on landmark translational research
breast cancer studies 2010-2011: Ready for
prime time?
Martine Piccart, BE
Update on neoadjuvant breast cancer trials
2010-2011: Lessons learnt
Gunter Von Minckwitz, DE
Discussion
14:00-15:10 Best abstracts session
Co-Chairs: Martine Piccart, BE and Daniel
F. Hayes, US
Mucin-1 protein and mRNA expression in breast
cancer patients treated with neoadjuvant
chemotherapy
Bruno V. Sinn, Berlin/DE
Discussant: Angelo Di Leo, IT
Gene modules and pathological complete
response to neoadjuvant chemotherapy in
breast cancer. A pooled analysis
Michail Ignatiadis, Brussels/BE
Assessment of response to neoadjuvant
chemotherapy with high resolution MRI at 3T:
Correlation with pathological response
Katja Pinker-Domenig, Vienna/AT
Prognostic Significance of Progesterone
Receptor-Positive Tumor Cells within
Immunohistochemically-defined Luminal A
Breast Cancer
Aleix Prat, Chapel Hill/US Discussant: TBC
Prospective Comparison of Risk Assessment
Tools in Early Breast Cancer: Correlation
Analysis from the Phase III WSG-Plan B Trial
Oleg Gluz, Moenchengladbach/DE
15:10-15:40 Coffee break
15:40-17:10 Metabolism and breast cancer
Co-Chairs: Angelo Di Leo, IT and Andrea
Alimonti, CH
Metabolism in malignant tumors: biology in
breast cancer
Tak W. Mak, CA
Insulin and IGFs: Mechanisms related to effects
of diet and metformin on breast cancer
Michael N. Pollak, CA
Implications for clinical development Alastair Thompson, GB
Discussion 3 | P a g e
17:10-17:50
Challenges in biomarker and drug
development: FGFR inhibitors in breast
cancer
Co-Chairs: José Baselga, US and
Sherene Loi, BE
Alteration of FGFR pathway in breast cancer Nicholas Turner, GB
FGFR inhibitors in breast cancer Fabrice André, FR
17:50-18:30 Welcome reception
18:30-19:30
Genomic Health Satellite symposium: Making personalized medicine a reality for
breast cancer patients: How to speed up the path for reimbursement
Friday, 4 May 2012
08:30-09:15 Keynote lecture
Co-Chairs: Mitchell Dowsett, GB and
Alastair Thompson, GB
Intratumor heterogeneity: A challenge for
personalized medicine?
Charles Swanton, GB
Clinical perspectives Jonas Bergh, SE
09:15-10:45
Can next-generation sequencing help to
solve the problem of intratumor
heterogeneity?

Co-Chairs: Christophe Klein, DE and
Christos Sotiriou, BE
NGS to decipher intratumor heterogeneity Peter Campbell, GB
Molecular heterogeneity of the minimal residual
disease
Christoph Klein, DE
Can NGS facilitate drug development? Matthew Ellis, US
Discussion
10:45-11:10 Coffee break
11:10-12:20 Best abstracts session
Co-Chairs: Larry Norton, US and Mitchell
Dowsett, GB
Independent Blinded Validation of the Genomic
Index of Sensitivity to Endocrine Therapy (SET)
Thomas Karn, Frankfurt/DE
Discussant: Mitchell Dowsett, GB
The role of AP-1 in endocrine-resistant breast
cancer
Luca Malorni, Prato/IT
Results of a randomized phase 2 study of PD
0332991, a cyclin-dependent kinase (CDK) 4/6
inhibitor, in combination with letrozole vs
letrozole alone for first-line treatment of
ER+/HER2- advanced breast cancer (BC)
Richard Finn, Los Angeles/US
Translational studies within the TAMRAD
randomized GINECO trial: Evidence for TORC1
activation marker as a predictive factor for
everolimus efficacy in metastatic breast cancer
(MBC)
Thomas Bachelot, Lyon/FR
Biology of Breast Cancer diagnosed in Young
Women: Pooled Gene Expression Analysis from
3522 Patients
Hatem Azim, Brussels/BE
Discussant: TBC
12:20-13:00 Lunch 4 | P a g e
13:00-14:00 Satellite symposium
14:00-15:00
Towards a further segmentation of triple
negative breast cancer (TNBC)?
Co-Chairs: Nadia Harbeck, DE and Larry
Norton, US
Molecular characterisation of TNBC gene
expression
Jorge Reis-Filho, GB
Mutational and clonal evolution in triple negative
breast cancers
Samuel Aparicio, CA
Discussion
15:00-16:15
Challenges in biomarker and drug
development: Targeting the host and
microenvironment in triple negative breast
cancer?
Co-Chairs: Giuseppe Curigliano, IT and
Peter C. Dubsky, AT
Development of immunotherapeutic approaches
in TNBC
Mark J. Smyth, AU
TNBC and the relationship to its
microenvironment
Charlotte Kuperwasser, US
Lessons learnt from biomarker development in
industry
Stefan Scherer, US
Discussion
16:15-17:20 Poster walk
17:20-18:30
Beyond PARPi for TNBC: other drug
targets
Co-Chairs: Angelo Di Leo, IT and Andrea
Alimonti, CH
Targeting DNA damage response and repair
(except parp)
Thomas Helleday, GB and SE
PTEN- a master regulator? Andrea Alimonti, CH
Drug development in TNBC: What did we
learn from recent failures and how can we
optimize future development?
Eric Winer, US
Discussion
18:30-19:30 Roche Satellite symposium: Successful patient outcomes in breast cancer
Saturday, 5 May 2012
08:00-09:15
Can gene arrays become a standard
procedure for daily practice?
Co-Chairs: Eric Winer, US and William
Fraser Symmans, US
Gene signatures: What’s new to predict outcome
and drug sensitivity?
Christos Sotiriou, BE
Are whole genome arrays feasible in daily
practice?
William Fraser Symmans, US
What criteria should be met before the
implementation of whole genome arrays in
clinical practice?
Daniel F. Hayes, US
Discussion
09:15-10:15
Trends in pathology research
Joint session BIG-ESMO-ESP
Co-Chairs: Jorge Reis-Filho, GB and
Tibor Tot, SE
New markers in pathology: Why and how Carsten Denkert, DE
Strategies for improving inter -and intralaboratory concordance and reproducibility
Giuseppe Viale, IT
Discussion
10:15-10:30 Award session
10:30-11:00 Coffee break5 | P a g e
11:00-13:00 Guidelines session
Co-Chairs: Sherene Loi, BE and Fabrice
André, FR
Which prognostic multigene signatures could be
helpful in the daily practice?
Charles Swanton, GB
Molecular subclasses of breast cancer: How do
we define them?
Jorge Reis-Filho, GB
13:00-13:15 Closing remarks
Fabrice André, FR and Sherene Loi, BE
Martine Piccart, BE and José Baselga, US

3 May - 5 May 2012
brussels
Belgium
meeting website